- Home
- AARD vs AMTX Comparison
AARD vs AMTX Comparison
Compare AARD & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- AMTX
- Stock Information
- Founded
- AARD 2017
- AMTX 2005
- Country
- AARD United States
- AMTX United States
- Employees
- AARD N/A
- AMTX N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- AMTX Major Chemicals
- Sector
- AARD Health Care
- AMTX Industrials
- Exchange
- AARD Nasdaq
- AMTX Nasdaq
- Market Cap
- AARD 186.3M
- AMTX 150.1M
- IPO Year
- AARD 2025
- AMTX N/A
- Fundamental
- Price
- AARD $16.08
- AMTX $2.65
- Analyst Decision
- AARD Strong Buy
- AMTX Strong Buy
- Analyst Count
- AARD 7
- AMTX 3
- Target Price
- AARD $31.43
- AMTX $17.00
- AVG Volume (30 Days)
- AARD 238.4K
- AMTX 1.0M
- Earning Date
- AARD 11-14-2025
- AMTX 11-11-2025
- Dividend Yield
- AARD N/A
- AMTX N/A
- EPS Growth
- AARD N/A
- AMTX N/A
- EPS
- AARD N/A
- AMTX N/A
- Revenue
- AARD N/A
- AMTX $223,574,000.00
- Revenue This Year
- AARD N/A
- AMTX $14.06
- Revenue Next Year
- AARD N/A
- AMTX $108.78
- P/E Ratio
- AARD N/A
- AMTX N/A
- Revenue Growth
- AARD N/A
- AMTX N/A
- 52 Week Low
- AARD $4.88
- AMTX $1.22
- 52 Week High
- AARD $19.58
- AMTX $4.73
- Technical
- Relative Strength Index (RSI)
- AARD 79.19
- AMTX 59.69
- Support Level
- AARD $10.75
- AMTX $2.19
- Resistance Level
- AARD $14.32
- AMTX $2.56
- Average True Range (ATR)
- AARD 1.07
- AMTX 0.20
- MACD
- AARD 0.58
- AMTX 0.03
- Stochastic Oscillator
- AARD 95.99
- AMTX 70.27
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About AMTX Aemetis Inc. (DE)
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.